AN2 Therapeutics, Inc. Stock Issued During Period, Value, New Issues
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- AN2 Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2023-09-30 was $65.48M.
- AN2 Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2022-06-30 was $9.53M.
- AN2 Therapeutics, Inc. stock issued during period, value, new issues for the quarter ending 2022-03-31 was $60.84M.
- AN2 Therapeutics, Inc. stock issued during period, value, new issues for fiscal 2023 was $65.48M.
| Period end | Stock Issued During Period, Value, New Issues 3 month | Stock Issued During Period, Value, New Issues 12 month |
|---|---|---|
| 2023-12-31 | $65.48M 10-K · filed 2025-03-25 | |
| 2023-09-30 | $65.48M 10-Q · filed 2024-11-13 | |
| 2022-06-30 | $9.53M 10-Q · filed 2022-11-09 | |
| 2022-03-31 | $60.84M 10-Q · filed 2023-05-11 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |